Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 3/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22887463 | 1.00 | KEAP1 (0.57) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL22887473 | 0.93 | KEAP1 (0.58) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL26975791 | 0.89 | LTA4H (0.56) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL22887464 | 0.89 | LTA4H (0.56) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL22887364 | 0.86 | KEAP1 (0.54) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL385247 | 0.85 | KDM4E (0.62) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL63569 | 0.82 | SMN1; SMN2 (0.72) | SMN1; SMN2GAAALDH1A1KDM4EHRH3 | |
| SCHEMBL8190316 | 0.82 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAALDH1A1KDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL20575882 | 0.81 | SMN1; SMN2 (0.70) | SMN1; SMN2GAAALDH1A1KDM4EHRH3 | |
| SCHEMBL22887508 | 0.81 | KDM4E (0.60) | KEAP1NFE2L2SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | UNIV INDIANA TRUSTEES (US) | 2022-05-12 | — | — | US | disclosed |
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11267780-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | KEAP1 100/4885NFE2L2 713/4885SMN1; SMN2 2073/4885 |
| US-11858889-B2 | Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease | ADM2, DDAH1, BHMT | KEAP1 100/4885NFE2L2 713/4885SMN1; SMN2 2073/4885 |
| US-20220144795-A1 | COMPOUND FOR MODULATING DDAH AND ADMA LEVELS, AS WELL AS METHODS OF USING THEREOF TO TREAT DISEASE | ADM2, DDAH1, BHMT | KEAP1 100/4885NFE2L2 713/4885SMN1; SMN2 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.